Compare JHI & ORMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | JHI | ORMP |
|---|---|---|
| Founded | 1971 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 119.3M | 117.8M |
| IPO Year | N/A | N/A |
| Metric | JHI | ORMP |
|---|---|---|
| Price | $13.74 | $3.67 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 29.5K | ★ 273.5K |
| Earning Date | 01-01-0001 | 11-13-2025 |
| Dividend Yield | ★ 6.80% | N/A |
| EPS Growth | N/A | ★ 838.25 |
| EPS | ★ 1.05 | 1.03 |
| Revenue | N/A | ★ $2,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $12.47 | ★ $3.58 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $11.63 | $1.82 |
| 52 Week High | $13.40 | $3.71 |
| Indicator | JHI | ORMP |
|---|---|---|
| Relative Strength Index (RSI) | 52.93 | 75.70 |
| Support Level | $13.70 | $3.32 |
| Resistance Level | $13.87 | $3.54 |
| Average True Range (ATR) | 0.11 | 0.20 |
| MACD | 0.02 | 0.05 |
| Stochastic Oscillator | 51.43 | 97.91 |
John Hancock Investors Trust is a United States-based diversified, closed-end management investment company. It seeks to generate income for distribution to its shareholders. The secondary objective of the company is capital appreciation. The portfolio composition of the fund comprises corporate bonds, U.S. government agencies, preferred securities, asset-backed securities, common stocks, short-term investments, and others. The company's portfolio includes Corporate Bonds, Term Loans, U.S Government Agency, and Others.
Oramed Pharmaceuticals Inc is a pharmaceutical company that is engaged in the research and development of pharmaceutical solutions with a technology platform that allows for the oral delivery of therapeutic proteins. developed an oral dosage form intended to withstand the harsh environment of the stomach and effectively deliver active biological insulin or other proteins. Its product pipeline includes ORMD-0801, ORMD-0801, and ORMD 0901.